Johnson & Johnson income statement

In fiscal 2025, Johnson & Johnson reported revenue of $94.19bn, up 6.0% on the year before and net income of $26.80bn, or $11.03 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Johnson & Johnson: income statement, annual
Fiscal year	2009Jan 2010	2010Jan 2011	2011Jan 2012	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Jan 2016	2016Jan 2017	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Jan 2021	2021Jan 2022	2022Jan 2023	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	61.9	61.6	65.0	67.2	71.3	74.3	70.1	71.9	76.5	81.6	82.1	82.6	78.7	80.0	85.2	88.8	94.2	99.3
Cost of revenue	—	—	—	—	—	—	—	—	25.4	27.1	27.6	28.4	23.4	24.6	26.6	27.5	30.3	32.2
Gross profit	43.5	42.8	44.7	45.6	49.0	51.6	48.5	50.1	51.0	54.5	54.5	54.2	55.3	55.4	58.6	61.4	63.9	67.1
Research and development	7.0	6.8	7.5	7.7	8.2	8.5	9.0	9.1	10.6	10.8	11.4	12.2	14.3	14.1	15.1	17.2	14.7	16.1
Selling, general and administrative	19.8	19.4	21.0	20.9	21.8	22.0	21.2	20.1	21.5	22.5	22.2	22.1	20.1	20.2	21.5	22.9	23.7	25.5
Operating income	16.6	17.7	13.8	15.0	16.4	21.6	—	—	—	—	—	—	—	—	—	—	—	—
Interest expense	0.5	0.5	0.6	0.5	0.5	0.5	0.6	0.7	0.9	1.0	0.3	0.2	0.2	0.3	0.8	0.8	1.0	1.0
Income before tax	15.8	16.9	12.4	13.8	15.5	20.6	19.2	19.8	17.7	18.0	17.3	16.5	19.2	19.4	15.1	16.7	32.6	17.7
Income tax	3.5	3.6	2.7	3.3	1.6	4.2	3.8	3.3	16.4	2.7	2.2	1.8	1.4	3.0	1.7	2.6	5.8	1.6
Net income	12.3	13.3	9.7	10.9	13.8	16.3	15.4	16.5	1.3	15.3	15.1	14.7	20.9	17.9	35.2	14.1	26.8	16.1
Diluted EPS	$4.40	$4.78	$3.49	$3.86	$4.81	$5.70	$5.48	$5.93	$0.47	$5.61	$5.63	$5.51	$7.81	$6.73	$13.72	$5.79	$11.03	$6.58
Diluted shares (average)	2,789m	2,789m	2,775m	2,813m	2,877m	2,864m	2,813m	2,789m	2,745m	2,729m	2,684m	2,671m	2,674m	2,664m	2,560m	2,429m	2,429m	2,445m
EBITDA	19.4	20.6	16.9	18.6	20.5	25.5	—	—	—	—	—	—	—	—	—	—	—	—

US$ billions unless shown otherwise. Fiscal quarters.

Johnson & Johnson: income statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	22.5	21.9	23.7	24.0	24.6	24.1	25.3	25.4
Cost of revenue	7.1	7.4	7.6	7.3	8.0	8.1	8.1	8.1
Gross profit	15.4	14.5	16.1	16.7	16.6	16.0	17.3	17.3
Research and development	5.3	3.2	3.5	3.7	4.3	3.5	3.7	4.7
Selling, general and administrative	6.5	5.1	5.9	5.9	6.8	6.0	6.4	6.3
Interest expense	0.1	0.2	0.3	0.2	0.2	0.3	0.3	0.2
Income before tax	3.9	13.6	6.5	7.5	5.0	6.0	6.7	0.0
Income tax	0.5	2.6	1.0	2.3	−0.2	0.8	1.2	−0.2
Net income	3.4	11.0	5.5	5.2	5.1	5.2	5.5	0.2
Diluted EPS	$1.41	$4.54	$2.29	$2.12	$2.09	$2.14	$2.27	$0.09

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: JNJ vs LLY JNJ vs MRK JNJ vs PFE

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Johnson & Johnson's SEC filings (10-K and 10-Q), retrieved October 23, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Johnson & Johnson.